Table 4.
Treatment group | Low (n = 34) | Pa | Medium (n = 35) | P | High (n = 27) | P | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline | Week 12 | Change from baseline | Baseline | Week 12 | Change from baseline | Baseline | Week 12 | Change from baseline | ||||
Less severe | 3.37 ± 0.90b | 3.05 ± 0.97 | − 0.32 ± 1.06 | 0.290 | 3.22 ± 0.73 | 3.28 ± 1.18 | 0.06 ± 1.21 | 0.001 | 2.64 ± 0.50 | 3.14 ± 2.11 | 0.50 ± 1.99 | 0.096 |
More severe | 5.83 ± 1.10 | 5.13 ± 1.81 | − 0.70 ± 1.33A | 5.85 ± 0.83 | 3.71 ± 1.36 | − 2.15 ± 1.73B | 4.51 ± 0.99 | 3.62 ± 1.12 | − 0.89 ± 1.88A |
aMann–Whitney U test comparing change from baseline of those women with more severe vasomotor symptoms at baseline to those with less severe symptoms within groups
bMean ± SD (all such values)
A,BValues with different superscript letters across a row are significantly different (one-way ANOVA with quadratic contrast analyses)